Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), we wish to inform you that the Board of Directors of NATCO Pharma Limited ('Company' or 'Demerged Company') has approved a Scheme of Arrangement between NATCO Pharma Limited ('Demerged Company'), Natco Crop Health Sciences Limited ('Resulting Company') and their respective shareholders and creditors ('Scheme') under Sections 230 to 232 read with other applicable provisions of the Companies Act, 2013, in its meeting held on March 24, 2026, after considering the recommendations of the Audit Committee and the Committee of the Independent Directors of the Company. The Appointed Date under the Scheme is 1st October 2026.